Invest in a Better Dental Anesthetic

Created for dentists, by dentists

Worldwide, people suffer 1.9 billion dental injections every year.⁶ With its patent-protected technology7, Balanced Pharma is poised to bring the first and only pH-balanced dental anesthetic to a $2.2 billion market for less painful, faster-acting, and more reliable injections.

Verified by CrowdCheck badge, Balanced Pharma Incorporated, April 14, 2022, Get in for $4/Share

Invest in a Better Dental Anesthetic

Created for dentists, by dentists

Verified by CrowdCheck badge, Balanced Pharma Incorporated, April 14, 2022, Get in for $4/Share

Worldwide, people suffer 1.9 billion dental injections every year.⁶ With its patent-protected technology7, Balanced Pharma is poised to bring the first and only pH-balanced dental anesthetic to a $2.2 billion market for less painful, faster-acting, and more reliable injections.

Market Research

Strong Positive Reaction from Dentists

See what dentists (our end users) think about our patent-protected technology7,8

diverse dentists smiling
Say they are likely to use Libracaine8, when available
0%
Think using Libracaine would increase referrals8
0%
Say they are likely to feature Libracaine on their website and in their marketing materials8
0%

Invest in a Better Dental Injection

Balanced Pharma is pioneering the movement toward less painful, faster-acting, more reliable dental injections.

Become an investor today!

young girl smiling with female dentist, holding up

The Problem

Dental Injections are Unnecessarily
Painful and Slow-Acting

86% of patients and 90% of dentists want an improved dental anesthetic2,3.

female patient, holding jaw after painful dental injection

Each Year, Patients Suffer Nearly 2 Billion Dental Injections

These injections are stressful for both patients and dentists, and for good reason:
  • The acid preservative in local anesthetic drugs causes pain during injection and a delayed anesthetic effect.
  • Local anesthetic pH can be 25,000 times more acidic than human tissue.
  • For dentists, this means uncomfortable patients, wasted time, and wasted money.

Painful injection

Long wait time

20% avg. failure rate

Time & money wasted

0%
Dentists report that current dental injections have a 20% average failure rate4
0%
58% of patients believe the injection is the worst part of the dental experience1
0%
86% of patients want a less-painful dental injection2
0%
90% of dentists want an improved dental anesthetic3

The Solution

The First and Only pH-Balanced
Dental Anesthetic

Our patent-protected technology7 can deliver a less painful, faster-acting, and more reliable5 dental anesthetic.

Introducing Libracaine® Dental9

The First and Only pH-Balanced Dental Anesthetic
The Convenience of a Standard Dental Cartridge

The Technology

Our Patent-Protected Libracaine® Cartridge

Because Libracaine will be supplied in a standard dental cartridge, dentists can seamlessly replace their current anesthetic with the new pH-balanced Libracaine Dental anesthetic9.

quotation marks

A pH-balanced anesthetic in a standard dental cartridge
will be a game changer.

- Jason Goodchild, DMD

Dr. Goodchild holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on the subject of dental pain management.

The Market

$2.2 Billion Market Opportunity6

$220 million estimated annual revenue for each 10% of market share.

744 Million Units per Year in Serviceable Available Markets

Current usage in our targeted dental markets—North America, Western Europe, Japan, and South Korea—is 744 million units. Total worldwide is 1.9 billion units1.

$220 Million Estimated Revenue for Each 10% of Market Share

BPI has a target average wholesale price of $3.00 per cartridge.

Additional Medical Market Potential

BPI’s patent-pending medical vial technology7 may allow later entry into dermatology, plastic surgery, emergency medicine, interventional radiology, and podiatry markets10.

technology investment background

Founder's Story

A Mission to Improve Patient Comfort

"Every patient deserves a less-painful injection."

- Scott Keadle, DDS | CEO, Balanced Pharma

A Need for Less Painful, Faster-Acting Dental Injections

Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.

He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.

A New Anesthetic. Created for Dentists, by Dentists.

Dr. Keadle invented patented technology7 to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol.  He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).

Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market.

Dr. Keadle and Dr. Chu walking in office, talking

Invest in a Better Dental Injection

Balanced Pharma is pioneering the movement toward less painful, faster-acting, more reliable dental injections.

Become an investor today!

The Team

Balanced Pharma Team

Our growing team is dedicated to excellence in our mission to improve patient comfort

bpi_scott_keadle-web

John S. Keadle, DDS

Chairman and CEO

Founder and CEO at Balanced Pharma, 30+ years as a dentist, practice owner and business executive

John Selig

John Selig

Board Director

Managing Partner at WaveEdge Capital, 25+ years in life science investment banking and M&A practice

Mark Sebree

Mark Sebree

Board Director,
Chief Development Officer

35+ years experience establishing and implementing strategy in the pharmaceutical industry

Eric Sherb

Eric Sherb

Chief Financial Officer

13 years experience in accounting advisory, auditing, and M&A; extensive experience in financial reporting

Jason Suggs

Jason Suggs

Chief Communications Officer

CEO at Orange Reef, 20+ years in brand strategy, communications, and technology

Alex Sadusky

Alex Sadusky

Senior Advisor—Commercial

CEO, TruBlu Dental; Former Dentsply Sirona Senior Executive; Former Senior External Advisor, McKinsey & Co. Pharma & Med Products Division

Nita Patel

Nita U. Patel, Ph.D.

Senior Advisor—CMC

SVP, Global Reg. Issues and Head of CMC, at ProPharma Group; 30+ years of R&D and pharmaceutical industry experience

Steve Jensen

Steve Jensen

Senior Advisor—Regulatory

EVP, Head of U.S. Regulatory Sciences, at ProPharma Group; 22+ years of pharmaceutical industry experience

bpi_brooks_thode-web

Brooks Thode

Cartridge Manufacturing

Business Development Director at Aenova, 19+ years in pharma manufacturing and business development

Sara Hanks

Sara Hanks, Esq.

Securities Counsel

CEO, CrowdCheck Law Firm

Byron Kirkland

Byron Kirkland, Esq.

Corporate Counsel

Managing Partner, Smith Anderson Law Firm

bpi_greg_carlin-web

Greg Carlin, Esq.

Intellectual Property Counsel

Partner, Meunier, Carlin, & Curfman Law Firm

Scientific Advisory Board

Bishr Al Dabagh

Bishr Al-Dabagh, MD, MBA, FAAD, FACMS

Scientific Advisor

Board-certified dermatologist (American Board of Dermatology), fellowship-trained dermatologic surgeon (American College of Mohs Surgery), and a fellow of the American Academy of Dermatology (AAD). Dr. Al-Dabagh has published over 20 peer-reviewed articles and book chapters.

Larina Chu, DDS, M-PA, CLS

Larina Chu, DDS, M-PA, CLS

Scientific Advisor

Dentist anesthesiologist serving the greater Hesperia, California area. Dr. Chu is a professional member of the American Board of Dental Anesthesiologists, the American Dental Association, the California Dental Association and the Tri-County Dental Society.

Mark Donaldson, Pharm D.

Mark Donaldson, Pharm.D.

Scientific Advisor

Associate Principal at Vizient Pharmacy Advisory Solutions, 17+ years as a recognized expert in dental pharmacology, He holds academic appointments at the University of Montana and the Oregon Health & Sciences University and serves on the editorial board of the Journal of the American Dental Association.  

Jay Reznik, DMD, MD

Jay B. Reznick, DMD, MD

Scientific Advisor

Director of the Southern California Center for Oral and Facial Surgery in Tarzana, California; Diplomate of the American Board of Oral and Maxillofacial Surgery; the first specialist in the U.S. to integrate CBCT and CAD/CAM in his practice; has been published extensively in dental and medical literature

John Robertson, DMD

John B. Roberson, DMD

Scientific Advisor

Oral & Maxillofacial Surgeon; CEO and Co-Founder of AAFDO (Accreditation Association For Dental Offices); CEO and Co-founder. of the Institute of Medical Emergency Preparedness; author and lecturer; selected as a CE Leader for Dentistry Today for 10 consecutive years.

Become a Shareholder in Balanced Pharma, Inc.

Invest in a Better Dental Anesthetic

Balanced Pharma is pioneering the movement toward faster-acting, less painful dental injections.

Become an investor today!

INVESTORS SHOULD ALWAYS CONDUCT THEIR OWN DUE DILIGENCE, NOT RELY ON THE FINANCIAL ASSUMPTIONS OR ESTIMATES DISPLAYED HEREIN, AND SHOULD ALWAYS CONSULT WITH A REPUTABLE FINANCIAL ADVISOR, ATTORNEY, ACCOUNTANT, AND ANY OTHER PROFESSIONAL THAT CAN HELP THEM TO UNDERSTAND AND ASSESS THE RISKS ASSOCIATED WITH ANY INVESTMENT OPPORTUNITY. ANY INVESTMENT INVOLVES SUBSTANTIAL RISKS. MAJOR RISKS, INCLUDING RELATED TO THE EQUITY PROTECTION AND/OR THE POTENTIAL LOSS OF SOME OR ALL PRINCIPAL, ARE DISCLOSED IN THE PRIVATE PLACEMENT MEMORANDUM FOR EACH APPLICABLE INVESTMENT.THE ABOVE MAY CONTAIN FORWARD-LOOKING STATEMENTS. ACTUAL RESULTS AND TRENDS IN THE FUTURE MAY DIFFER MATERIALLY FROM THOSE SUGGESTED OR IMPLIED BY ANY FORWARD-LOOKING STATEMENTS IN THE ABOVE DEPENDING ON A VARIETY OF FACTORS. ALL WRITTEN AND ORAL FORWARD-LOOKING STATEMENTS ATTRIBUTABLE TO US OR PERSONS ACTING ON OUR BEHALF ARE EXPRESSLY QUALIFIED IN THEIR ENTIRETY BY THE PREVIOUS STATEMENTS. EXCEPT FOR ANY OBLIGATIONS TO DISCLOSE INFORMATION AS REQUIRED BY APPLICABLE LAWS, WE UNDERTAKE NO OBLIGATION TO UPDATE ANY INFORMATION CONTAINED ABOVE OR TO PUBLICLY RELEASE THE RESULTS OF ANY REVISIONS TO ANY STATEMENTS THAT MAY BE MADE TO REFLECT EVENTS OR CIRCUMSTANCES THAT OCCUR, OR THAT WE BECOME AWARE OF, AFTER THE DATE OF THE PUBLISHING OF THE ABOVE.”ALL SECURITIES-RELATED ACTIVITY IS CONDUCTED THROUGH DALMORE GROUP, LLC (“DALMORE”), A REGISTERED BROKER-DEALER AND MEMBER FINRA/SIPC. DALMORE DOES NOT MAKE INVESTMENT RECOMMENDATIONS AND ACTS ONLY AS THE BROKER/DEALER OF RECORD FOR THE OFFERING LISTED. YOU CAN REVIEW THE BACKGROUND OF OUR BROKER-DEALER AND OUR INVESTMENT PROFESSIONALS ON FINRA’S BROKERCHECK

(1) “58% OF PATIENTS BELIEVE THE INJECTION IS THE WORST PART OF THE DENTAL EXPERIENCE,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)

(2) “WHAT PATIENTS WANT: A LESS-PAINFUL DENTAL INJECTION: 86%,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)

(3) “OVER 90% OF DENTISTS REPORT A DESIRE FOR CURRENT ANESTHETICS TO BE MORE RELIABLE, LESS PAINFUL, OR FASTER ACTING,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181;

(4) “DENTISTS REPORT AN INITIAL ANESTHETIC FAILURE RATE OF 20%,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181

(5) 2018 META-ANALYSIS: SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN; GUO ET AL FROM UNIVERSITY OF SOUTHERN CALIFORNIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN (VAS) COMPARED WITH NON-BUFFERED LIDOCAINE IN INFERIOR ALVEOLAR NERVE BLOCK.”; 2017 CLINICAL STUDY: REDUCES THE PAIN ON INJECTION; PHERO ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE REDUCES THE PAIN ON INJECTION WITH A MAXILLARY FIELD BLOCK AND RESULTS IN SIMILAR LENGTHS OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE.” 2017 CLINICAL STUDY: LOWER PAIN ON INJECTIONS. WARREN ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “AFTER MANDIBULAR NERVE BLOCK, BUFFERED 1% LIDOCAINE CAN PRODUCE SIMILAR DURATION OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE AND LOWER PAIN ON INJECTIONS.”; 2019 META-ANALYSIS: 2.29 TIMES MORE RELIABLE IN INFLAMED TEETH; KATTAN ET AL FROM UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LOCAL ANESTHETICS HAVE 2.29 TIMES GREATER LIKELIHOOD OF ACHIEVING SUCCESSFUL ANESTHESIA [IN PULPALLY INVOLVED TEETH].”

(6) SDM NORTHCOAST, LLC REPORT, “INJECTABLE CARPULES MARKET SIZE ANALYSIS, UNITED STATES, CANADA, MEXICO, 2019 UNITS”, JULY 15, 2021; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY,” SEPTEMBER 20, 2021; BALANCED PHARMA INTERNAL ESTIMATES

(7) BPI OWNS THE FOLLOWING GRANTED PATENTS AND PENDING PATENT APPLICATIONS: U.S. PATENT NO. 11,305,064 (ISSUED APRIL 19TH, 2022); U.S. APPLICATION NO. 17/722,016; INTERNATIONAL PCT APPLICATION NO. PCT/IB2018/052598; CANADIAN APPLICATION NO. 3,111,347 (CANADIAN NATIONAL PHASE OF PCT/IB2018/052598); EUROPEAN APPLICATION NO. 18897951.2 (EUROPEAN REGIONAL PHASE OF PCT/IB2018/052598); JAPANESE APPLICATION NO. 2020-556351 (JAPANESE NATIONAL PHASE OF PCT/IB2018/052598); KOREAN APPLICATION NO. 10-2020-7021685 (REPUBLIC OF KOREA NATIONAL PHASE OF PCT/IB2018/052598); U.S. APPLICATION NO. 16/655,362; U.S. APPLICATION NO. 63/233,879; BPI ALSO OWNS ONE TRADEMARK APPLICATION, U.S. APPLICATION NO. 88/198,808, PENDING FOR THE LIBRACAINE MARK.

(8) OLSON RESEARCH GROUP, “U.S. DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13TH, 2021,” TOTA SAMPLE SIZE: 181 DENTISTS; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY, CONDUCTED FOR BALANCED PHARMA, SEPTEMBER 20, 2021,” TOTAL SAMPLE SIZE: 433 DENTISTS

(9) LIBRACAINE HAS NOT YET BEEN APPROVED BY FDA AND IS NOT AVAILABLE FOR SALE.

(10) BPI HAS NOT YET BEGUN TRIALS TO DETERMINE WHETHER ITS TECHNOLOGY CAN ADAPT TO DERMATOLOGY, PLASTIC SURGERY, EMERGENCY MEDICINE, INTERVENTIONAL RADIOLOGY, AND PODIATRY.

Balanced Pharma, Inc.
18204 Mainsail Pointe
Cornelius, NC 28031

investor@balancedpharma.com
(980) 231-4318

Balanced Pharma, Inc.
18204 Mainsail Pointe
Cornelius, NC 28031

investor@balancedpharma.com
(980) 231-4318

Get the Balanced Pharma Investor Brief

Sign up for updates and learn more about the opportunity to invest in Balanced Pharma.